Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb;31(2):151-7.
doi: 10.1016/j.reprotox.2010.11.006. Epub 2010 Dec 2.

Preterm birth, fetal growth, and age at menarche among women exposed prenatally to diethylstilbestrol (DES)

Elizabeth E Hatch  1 , Rebecca Troisi, Lauren A Wise, Linda Titus-Ernstoff, Marianne Hyer, Julie R Palmer, William C Strohsnitter, Stanley J Robboy, Diane Anderson, Raymond Kaufman, Ervin Adam, Robert N Hoover
Affiliations

Preterm birth, fetal growth, and age at menarche among women exposed prenatally to diethylstilbestrol (DES)

Elizabeth E Hatch et al. Reprod Toxicol. 2011 Feb.

Abstract

Diethylstilbestrol (DES), a synthetic estrogen used in pregnancy during the 1950s and 1960s, provides a model for potential health effects of endocrine disrupting compounds in the environment. We evaluated prenatal exposure to DES, based on medical record review, in relation to gestational length, fetal growth, and age at menarche in 4429 exposed and 1427 unexposed daughters. DES exposure was associated with an increase in preterm birth (odds ratio (OR)=2.97; 95% CI=2.27, 3.87), and a higher risk of small for gestational age (SGA) (OR=1.61; 95% CI=1.31, 1.98). The association between DES exposure and early menarche was borderline, with stronger effects when early menarche was defined as ≤ 10 years (OR=1.41 95% CI=0.97, 2.03) than defined as ≤ 11 years (OR=1.16; 95% CI=0.97, 1.39). This study provides evidence that prenatal DES exposure was associated with fetal growth and gestational length, which may mediate associations between DES and health outcomes in later life.

PubMed Disclaimer

References

    1. Dieckmann WJ, Davis ME, Rynkiewicz LM, Pottinger RE. Does the administration of diethylstilbestrol during pregnancy have therapeutic value? Am J Obstet Gynecol. 1953 Nov;66(5):1062–81. - PubMed
    1. Ferguson JH. The importance of controls in a clinical experiment; stilbestrol therapy in pregnancy. Obstet Gynecol. 1954 Apr;3(4):452–7. - PubMed
    1. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971 Apr 15;284(15):878–81. - PubMed
    1. Heinonen OP. Diethylstilbestrol in pregnancy. Frequency of exposure and usage patterns. Cancer. 1973 Mar;31(3):573–7. - PubMed
    1. Palmlund I, Apfel R, Buitendijk S, Cabau A, Forsberg JG. Effects of diethylstilbestrol (DES) medication during pregnancy: report from a symposium at the 10th international congress of ISPOG. J Psychosom Obstet Gynaecol. 1993 Mar;14(1):71–89. - PubMed

Publication types

Substances